RxDoctor Payments Data

Donald Eagle, MD

Family Medicine · Eustis, FLNPI 1326086760

Payments from drug & device makers

$2,703in general payments, 2019–2025

Across 118 payments — averaging $22.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$534
  • AstraZeneca$534
  • Amarin Pharma, Inc.$248
  • Novo Nordisk$215
  • Bayer$166
  • GSK$150
  • plus $856 from 17 others

What the payments were for

  • Food & beverage$2,703100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,703 in reported general payments places this provider in the 80th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$87,642
Medicare patients
353
Services billed
1,133

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban160$181,634
JanuviaSitagliptin Phosphate60$85,452
JardianceEmpagliflozin38$56,659
XareltoRivaroxaban52$50,750
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$46,421
FarxigaDapagliflozin Propanediol32$32,665
OzempicSemaglutide21$31,542
Repatha SureclickEvolocumab34$27,554
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$19,928
BriviactBrivaracetam12$16,561
BrilintaTicagrelor24$14,860
Rosuvastatin Calcium783$10,382
Repatha SyringeEvolocumab14$9,581
SymbicortBudesonide/Formoterol Fumarate18$9,504
Atorvastatin Calcium992$9,436

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$131$181,634160 claims
MerckJanuvia$17$85,45260 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta, Symbicort$534$76,95990 claims
Boehringer IngelheimJardiance$22$56,65938 claims
GSKTrelegy Ellipta, Anoro Ellipta$150$54,14842 claims
Johnson & JohnsonXarelto$102$50,75052 claims
Novo NordiskOzempic$215$31,54221 claims
AbbVieLinzess, Synthroid$41$11,97469 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Eustis

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →